First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma

NCT03287310 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: GSK3511294
DRUG: Placebo
DRUG: Salbutamol/albuterol

Sponsor

GlaxoSmithKline